CYP19A1 and breast carcinoma: Moreover, as the active binding sites of ER and aromatase present similar sizes and contain equivalent residues, suggesting the binding of the same ligands [1], molecules that present dual anti-estrogen and anti-aromatase features are posed as future drugs for ER+ breast cancer therapy [28,29].